Serotonin transporter (SERT) gene polymorphism in Parkinson’s disease
Background: Parkinson disease (PD) is the second most common neurodegenerative disorder with a prevalence of about 2% in persons older than 65 years of age. Neurodegenerative process in PD is not restricted to the dopaminergic neurons of the substantia nigra but also affects serotoninergic neuro...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Yayinevi
2004-06-01
|
Series: | Türk Nöroloji Dergisi |
Subjects: | |
Online Access: | https://www.journalagent.com/tjn/pdfs/TJN_10_3_201_205.pdf |
Summary: | Background: Parkinson disease (PD) is the second most common neurodegenerative
disorder with a prevalence of about 2% in persons older than
65 years of age. Neurodegenerative process in PD is not restricted to the
dopaminergic neurons of the substantia nigra but also affects serotoninergic
neurons. It has been shown that PD brains with Lewy bodies in the substantia
nigra also had Lewy bodies in the raphe nuclei. The re-uptake of 5HT
released into the synaptic cleft is mediated by the 5HT transporter (SERT).
The SERT gene has been mapped to the chromosome of 17q11.1-q12 and
has two main polymorphisms: intron two VNTR polymorphism and promoter
region 44 bp insertion/deletion polymorphism.
Objective: In this study we investigated whether two polymorphic regions
in the serotonin transporter gene are associated with PD. Material and Method: After obtaining informed consent, blood samples
were collected from 76 patients and 54 healthy volunteers. Genomic DNA
was extracted from peripheral leucocytes using standard methods. The
SERT gene genotypes were determined using polymerase chain reaction
(PCR) method.
Results: Based on the intron 2 VNTR polymorphism of SERT gene, the
distribution of 12/12, 12/10 and 10/10 genotypes were found as, 56.6 %,
35.5 %, 7.9 % in patients whereas this genotype distribution in control
group was 40.7 %, 46.3 % and 13 %, respectively. According to 5-HTTLPR
polymorphism, the distribution of L/L, L/S and S/S genotypes were found
as 27.6 % 51.3 % and 21.1 % in patients whereas this genotype distribution
in control group was 33.4 %, 50.0 % and 16.6 %, respectively. Despite the
fact that the genotype distribution of SERT gene polymorphism in patients
and control group seemed to be different from each other, this difference
was not found to be statistically significant.
Conclusion: This finding suggests that polymorphisms within the SERT
gene do not play a major role in PD susceptibility in the Turkish population. |
---|---|
ISSN: | 1301-062X 1309-2545 |